Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced or metastatic squamous non-small cell lung cancer
CTR20231272Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-free survival. Started Aug 2023; status: active.
02
Drugs
ivonescimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20231272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231272.